[1] 中国医师协会介入医师分会.中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版)[J].临床肝胆病杂志,2019,35(12):2694-2699.
[2] 邹松龙,胥莹.经颈静脉肝内门体分流术治疗肝硬化门静脉高压症的预后评估[J].临床肝胆病杂志,2019,35(1):201-204.
[3] 王文生,慕之勇,王军,等.经颈静脉肝内门体分流术后抗凝治疗:系统评价和meta分析[J].胃肠病学, 2020,25(8):483-488.
[4] 吕一帆,刘福全.经颈静脉肝内门体分流术后抗凝治疗现状[J].中国介入影像与治疗学,2021,18(10):622-626.
[5] Pettinari I,Vukotic R,Stefanescu H,et al.Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis[J].Am J Gastroenterol,2019,114(2):258-266.
[6] 赵平,黎涛,谢吉良,等.早期抗凝干预用于经颈静脉肝内门体静脉支架分流术联合PSE治疗肝硬化患者价值探讨[J].实用肝脏病杂志,2020,23(1):82-85.
[7] 姚欣,周昊,汤善宏,等.经颈静脉肝内门体分流术后支架功能障碍的原因分析及处理策略[J].临床肝胆病杂志,2019,35(5):1052-1056.
[8] Inchingolo R, Posa A, Mariappan M, et al. Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: a comprehensive review[J]. World J Gastroenterol,2020,26(34): 5060-5073.
[9] 中华医学会消化病学分会消化微创介入协作组.经颈静脉肝内门体静脉分流术治疗门静脉高压专家共识[J].胃肠病学,2023,28(6): 344-363.
[10] Jahangiri Y,Kerrigan T,Li L,et al.Risk factors for stent graft thrombosis after transjugular intrahepatic portosystemic shunt creation[J].Cardiovasc Diagn Ther,2017,7(Suppl 3):S150-S158.
[11] Wan Y M,Li Y H,Xu Y,et al.Predictors of shunt dysfunction and overall survival in patients with variceal bleeding treated with transjugular portosystemic shunt creation using the fluency stent graft[J].Acad Radiol,2018,25(7):925-934.
[12] 蒋明远,黄华,路明亮,等.抗凝药物在经颈静脉肝内门体分流术后的应用[J].临床肝胆病杂志,2018,34(10):2241-2244. |
